| Source: |
| Type: |
| The p42 protein often refers to a specific isoform of the mitogen-activated protein kinase (MAPK) pathway, particularly p42 MAPK, which is also known as extracellular signal-regulated kinase 2 (ERK2). This protein plays a crucial role in various cellular processes, including proliferation, differentiation, and survival. The activation of p42 MAPK has been associated with various types of cancer, including melanoma, breast cancer, and colorectal cancer. p42—which is commonly used to refer to the ~42 kDa isoform of extracellular signal‑regulated kinases (ERK), often designated as ERK2 (p42 MAPK)—in cancer. This summary covers its expression trends, prognostic implications, and functional roles in tumor biology. Note that the MAPK/ERK pathway is complex and highly context‑dependent, with ERK2 (p42) frequently working in concert with its counterpart ERK1 (p44) to regulate diverse cellular processes. In many cancers, the MAPK/ERK pathway is hyperactivated due to upstream mutations (e.g., in RAS or BRAF), leading to increased levels of active (phosphorylated) p42. – While the total expression of ERK2 may be relatively stable, the activated/phosphorylated form is frequently elevated, reflecting increased signaling activity. – This activation is observed in a variety of cancers including melanoma, colorectal cancer, lung cancer, and thyroid cancer. p42 is not exactly the same as "ERK" in general but is closely related. In many contexts, p42 refers specifically to the 42‑kDa isoform of the extracellular signal-regulated kinases (ERKs), often known as ERK2. Typically, cells express two closely related isoforms of ERK: one is about 44 kDa (ERK1, sometimes called p44) and the other is about 42 kDa (ERK2, or p42). Both of these are members of the mitogen-activated protein kinase (MAPK) family and play key roles in cellular signaling. So, when someone refers to p42 in the context of MAPK signaling, they are usually talking about ERK2, whereas "ERK" can be used to refer to both isoforms (ERK1 and ERK2) collectively. |
| Cyclooxygenase (COX)-2 overexpression has been noted in various cancers.
PI3Ks/AKT pathways are over-activated in several types of cancers. EGFR altered activity has been noted in various pathological conditions. However, its regulation is an important step in the inhibition of cancer. In this regard, EGCG shows a pivotal role in the inhibition of EGFR activity. Activating protein-1 transcription factor has been associated with pathogenesis including cancer. Activation of the sonic hedgehog (Shh) pathway is required for the growth of numerous tissues and organs and recent evidence indicates that this pathway is often recruited to stimulate growth of cancer stem cells (CSCs) and to orchestrate the reprogramming of cancer cells via epithelial mesenchymal transition (EMT). Increased expression of Nanog has been associated with the aggressive nature of certain cancers, highlighting its role in promoting cancer stem cell characteristics. The aberrant hedgehog (Hh)/GLI signaling pathway causes the formation and progression of a variety of tumors. The process of cell apoptosis is often accompanied by the destruction of mitochondrial transmembrane potential, which is widely regarded as one of the earliest events in the process of cell apoptosis. Human malignancies frequently exhibit mutations in the TGF-β pathway, and overactivation of this system is linked to tumor growth by promoting angiogenesis and inhibiting the innate and adaptive antitumor immune responses50. Several studies have demonstrated that high cyclin D1 expression was observed in cancers including breast, lung, prostate, lymph node and colorectal cancers [23–25]. The oncogene c-myc, which is frequently over-expressed in cancer cells, is involved in the transactivation of most of the glycolytic enzymes including lactate dehydrogenase A (LDHA) and the glucose transporter GLUT1 [51,52]. Thus, c-myc activation is a likely candidate to promote the enhanced glucose uptake and lactate release in the proliferating cancer cell. Vimentin is overexpressed in various epithelial cancers, including prostate cancer, gastrointestinal tumors, tumors of the central nervous system, breast cancer, malignant melanoma, and lung cancer. Vimentin’s overexpression in cancer correlates well with accelerated tumor growth, invasion, and poor prognosis; however, the role of vimentin in cancer progression remains obscure. Heat shock proteins (HSPs) are normally induced under environmental stress to serve as chaperones for maintenance of correct protein folding but they are often overexpressed in many cancers, including breast cancer. Since NQO1 is highly expressed in many solid tumors, including via upregulation of Nrf2, the design of compounds activated by NQO1 and NQO1-targeted drug delivery have been active areas of research. Since increased Nrf2 gene expression is one of the main mechanisms of cancer cells in resisting chemotherapeutic drugs and survival in oxidative conditions; finding compounds with the ability to suppress Nrf2 gene expression with minimum side effects can be considered an important strategy for increasing the sensitivity of cancer cells to chemotherapy. Overexpression of c-met stimulates proliferation, migration and invasion in various types of cancer including prostate cancer. Overexpression of TGFα and EGFR by many carcinomas correlates with the development of cancer metastasis, resistance to chemotherapy and poor prognosis. More than 50% of human cancers have a mutated nonfunctional p53. |
| 1316- | SIL, | Chemo, | Silymarin and Cancer: A Dual Strategy in Both in Chemoprevention and Chemosensitivity |
| - | Analysis, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:26 Cells:% prod#:% Target#:481 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid